Mainboard · BSE and NSEDraft filed

HINDUSTAN LABORATORIES LIMITED IPO: dates, price band, lot size, objects of the issue

Get updates on this IPO

Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.

Dates, allotment, listing and analyst views. Stop anytime.

By continuing you agree to the Terms and Privacy policy

Updated Sun 15 Nov 2026, 8:04 pm IST · Source: DRHP dated Sat 3 Jan 2026

Key facts

Price band
Not announced
Lot size
Not announced
Lot amount at the upper band
Not announced
Issue size at the upper band
1,41,00,000 shares (Amount not stated in the draft)
DRHP dated Sat 3 Jan 2026, page 82
Fresh issue
50,00,000 shares (Amount not stated in the draft)
DRHP dated Sat 3 Jan 2026, page 82
Offer for sale
91,00,000 shares (Amount not stated in the draft)
DRHP dated Sat 3 Jan 2026, page 82
Bid dates
Not announced
Listing date
Not announced
Risk factors
84
DRHP dated Sat 3 Jan 2026, page 80
Proposed exchanges
BSE and NSE

Timeline (IST)

  1. Draft filedTue 13 Jan 2026 confirmedDRHP dated Sat 3 Jan 2026
  2. OpensDates to be announced
  3. ClosesDates to be announced
  4. AllotmentDates to be announced
  5. Refund and unblockDates to be announced
  6. ListingDates to be announced

Objects of the issue

ObjectAmount
Funding the working capital requirements of our Company₹72.50 crore
General corporate purposesNot stated in the draft
TotalNot stated in the draft

The offer for sale goes to the selling shareholders, not the company. DRHP dated Sat 3 Jan 2026, page 107

Company and promoters

As described in the DRHP

We are an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework.

DRHP dated Sat 3 Jan 2026, page 24

Promoters

  • 3 individual promoters

DRHP dated Sat 3 Jan 2026, page 24

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group99.99%Not stated in the DRHP

DRHP dated Sat 3 Jan 2026, page 101

Financials (restated)

ItemFor the period ended September 30, 2025For the year ended March 31, 2025For the year ended March 31, 2024For the year ended March 31, 2023
Revenue from operations₹112.63 crore₹219.75 crore₹186.37 crore₹172.34 crore
Profit after tax₹18.24 crore₹41.27 crore₹34.14 crore₹22.25 crore
Net worth₹197.01 crore₹178.74 crore₹137.34 crore₹103.15 crore
Total borrowingsNot stated in the draftNot stated in the draftNot stated in the draftNot stated in the draft

DRHP dated Sat 3 Jan 2026, page 86

Who is selling in the offer for sale

Selling shareholderTypeShares offeredAmount at the upper band
Individual shareholderIndividual91,00,000Not announced
Total offer for saleNot stated in the draft

DRHP dated Sat 3 Jan 2026, page 82

Peer comparison (as in the DRHP)

Name of CompanyFace Value (₹ per share)P/EEPS (₹) BasicEPS (₹) DilutedRoNW (%)NAV (₹ per share)Total income (₹ in million)
Hindustan Laboratories Limited10[●]8.288.2826.11%35.852,273.72
Ajanta Pharma Limited235.2573.5673.5325.02%301.597,778.96
Syncom Formulations (India) Limited125.700.570.5715.69%3.644,824.47
Windlas Biotech Limited525.7029.1928.8712.76%243.1847,426.00

Reproduced from the DRHP dated Sat 3 Jan 2026, page 118; InsightPier adds no figures

Risk factors

84 total
  1. The company faces strong competition from other generic medicine suppliers in India (DRHP page 35)
  2. The business depends on a single manufacturing facility at Palghar and its operating risks (DRHP page 36)
  3. Most revenue comes from government customers won through tenders; losing them would hurt the business (DRHP page 36)
  4. A small number of customers account for much of the revenue (DRHP page 38)
  5. Future growth depends on adding new generic products on time and at reasonable cost (DRHP page 39)

All 84 risk factors, DRHP pages 35 to 81

Offer document

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts